Virax Biolabs Group Limited
VRAX · NASDAQ
9/30/2025 | 3/31/2025 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $2 | $1 | $5 | $80 |
| % Growth | 16.7% | -72.2% | -93.8% | – |
| Cost of Goods Sold | $217 | $48 | $11 | $40 |
| Gross Profit | -$215 | -$47 | -$6 | $40 |
| % Margin | -13,396.4% | -3,381.2% | -130.7% | 50.1% |
| R&D Expenses | $1,380 | $1,053 | $726 | $1,153 |
| G&A Expenses | $0 | $2,184 | $2,146 | $2,320 |
| SG&A Expenses | $990 | $2,184 | $2,146 | $2,287 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $33 |
| Other Operating Expenses | $0 | $0 | $0 | $390 |
| Operating Expenses | $2,370 | $3,237 | $2,872 | $3,830 |
| Operating Income | -$2,585 | -$3,284 | -$2,879 | -$3,790 |
| % Margin | -160,788.2% | -238,316.8% | -58,124.2% | -4,742.6% |
| Other Income/Exp. Net | -$31 | -$27 | -$14 | -$35 |
| Pre-Tax Income | -$2,617 | -$3,311 | -$2,893 | -$3,825 |
| Tax Expense | -$274 | $0 | -$137 | $0 |
| Net Income | -$2,339 | -$3,305 | -$2,756 | -$3,824 |
| % Margin | -145,446% | -239,827.3% | -55,651.7% | -4,784.7% |
| EPS | -0.49 | -0.76 | -0.89 | -1.71 |
| % Growth | 35.5% | 14.6% | 48% | – |
| EPS Diluted | -0.49 | -0.76 | -0.89 | -1.71 |
| Weighted Avg Shares Out | 4,763 | 4,357 | 3,097 | 2,233 |
| Weighted Avg Shares Out Dil | 4,763 | 4,357 | 3,104 | 2,238 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $31 | $33 | $26 | $17 |
| Depreciation & Amortization | $217 | $145 | $112 | $85 |
| EBITDA | -$2,369 | -$3,139 | -$2,767 | -$3,723 |
| % Margin | -147,336.7% | -227,823.3% | -55,861.2% | -4,658.2% |